The Bruneian

Abbott profit jumps on COVID testing demand, strong medical device sales


Abbott Laboratori­es reported a rise in quarterly profit on Wednesday helped by strong demand for its COVID-19 tests and a rebound in medical device sales.

Abbott, which provides COVID-19 testing kits and facilities, benefited from a surge in testing demand as cases of the highly transmissi­ble Omicron variant in the United States reached record levels in January.

Still, the company left its fullyear adjusted earnings forecast unchanged.

COVID-19 test kits brought in revenue of $3.3 billion in the quarter, boosting total sales at its diagnostic­s business, which grew 31.7% on a reported basis.

A rebound in demand for elective procedures boosted sales of medical devices as coronaviru­s cases dropped in the latter half of the quarter.

Abbott now forecast $4.5 billion in COVID-19 testing sales this year, which it expects will occur largely in the first half of the year.

The Illinois-based company reiterated that it expects 2022 adjusted profit per share to be at least $4.70.

 ?? ??

Newspapers in English

Newspapers from Brunei